Target sequences for synthetic molecules
AssigneeLife Technologies Corporation
InventorGeorge Hanson
Life of this patent
Estimating the term…
Abstract
The invention is based on the discovery that certain biarsenical molecules react with specified target sequences, thereby providing a facile means for labeling polypeptides containing the target sequence. The invention is useful in creating stable mammalian cell lines expressing a certain tetracysteine tagged polypeptides, thereby overcoming toxicity associated with native tetracysteine. In addition, the invention allows for orthogonal labeling of polypeptides, thereby allowing for the observation of protein-protein interactions and conformational changes in proteins, for example.
Claims23
A method of labeling a carrier molecule, comprising:
- a) providing a bonding partner comprising the carrier molecule and a target sequence, and
- b) contacting the bonding partner with a biarsenical molecule under conditions wherein the biarsenical molecule reacts with the target sequence, wherein the target sequence comprises Cys-Cys-X1-X1-X2-X1-X3-X1-X1-Cys-X1-Cys-X2 (SEQ. ID NO:
- 3), wherein:
- X1 is an amino acid having a non-polar side chain,
- X2 is an amino acid having a basic side chain, and
- X3 is an amino acid having a non-ionic polar side chain, and
- wherein the biarsenical molecule has the formula:
- and tautomers, anhydrides, and salts thereof;
- wherein:
- each X1 or X2 is independently Cl, Br, I, ORa, or SRa, or
- X1 and X2 together with the arsenic atom form a ring having the formula:
- Ra is H, C1-C4 alkyl, CH2CH2OH, CH2COOH, or CN;
- Z is 1,2-ethanediyl, 1,2-propanediyl, 2,3-butanediyl,
- 1,3-propanediyl, 1,2 benzenediyl, 4-methyl-1,2-benzenediyl,
- 1,2-cyclopentanediyl, 1,2-cyclohexanediyl, 3-hydroxy-1,2-propanediyl, 3-sulfo-1,2-propanediyl, or 1,2-bis(carboxy)-1,2-ethanediyl;
- Y1 and Y2 are each independently H or CH3, or
- Y1 and Y2 together form a ring such that the biarsenical molecule has the formula
- wherein:
- M is O, S, CH2, C(CH3)2, or NH;
- R1 and R2 are each independently ORa, OAc, NRaRb, or H;
- R3 and R4 are each independently H, F, Cl, Br, I, ORa, or Ra;
- or
- R1 together with R3, or R2 together with R4, or both, form a ring in which
- (i) one of R1 or R3 is C2-C3 alkyl and the other is NRa and
- (ii) one of R2 and R4 is C2-C3 alkyl and the other is NRa;
- Rb is H, C1-C4 alkyl, CH2CH2OH, CH2COOH, or CN;
- Q is CRaRb, CRaORb, C═O, or a spirolactone having the formula:
- wherein the Spiro linkage is formed at C1.
A method of purifying a bonding partner, comprising:
- a) providing a bonding partner comprising a target sequence wherein the target sequence comprises Cys-Cys-X1-X1-X1-X1-X3-X1-X1-Cys-X1-Cys-X2 (SEQ. ID NO:
- 3), wherein:
- X1 is an amino acid having a non-polar side chain,
- X2 is an amino acid having a basic side chain, and
- X3 is an amino acid having a non-ionic polar side chain, and
- wherein the target sequence reacts with a biarsenical molecule having the structure:
- and tautomers, anhydrides, and salts thereof;
- wherein:
- each X1 or X2 is independently Cl, Br, I, ORa, or SRa, or
- X1 and X2 together with the arsenic atom form a ring having the formula:
- Ra is H, C1-C4 alkyl, CH2CH2OH, CH2COOH, or CN;
- Z is 1,2-ethanediyl, 1,2-propanediyl, 2,3-butanediyl, 1,3-propanediyl,
- 1,2 benzenediyl, 4-methyl-1,2-benzenediyl, 1,2-cyclopentanediyl,
- 1,2-cyclohexanediyl, 3-hydroxy-1,2-propanediyl, 3-sulfo-1,2-propanediyl, or
- 1,2-bis(carboxy)-1,2-ethanediyl;
- Y1 and Y2 are each independently H or CH3, or
- Y1 and Y2 together form a ring such that the biarsenical molecule has the formula
- wherein:
- M is O, S, CH2, C(CH3)2, or NH;
- R1 and R2 are each independently ORa, OAc, NRaRb, or H;
- R3 and R4 are each independently H, F, Cl, Br, I, ORa, or Ra;
- or
- R1 together with R3, or R2 together with R4, or both, form a ring in which
- (i) one of R1 or R3 is C2-C3 alkyl and the other is NRa and
- (ii) one of R2 and R4 is C2-C3 alkyl and the other is NRa;
- Rb is H, C1-C4 alkyl, CH2CH2OH, CH2COOH, or CN;
- Q is CRaRb, CRaORb, C═O, or a spirolactone having the formula:
- wherein the Spiro linkage is formed at C1;
- b) contacting the bonding partner with the biarsenical molecule, wherein the biarsenical molecule is coupled to a solid phase, and
- c) eluting the bonding partner from the biarsenical molecule by contacting the biarsenical molecule with a dithiol.
Dependencies are inferred from the claim text.